Physician profile
Amy E Witt
NPI 1932208006
$18,367.79
in general payments reported to CMS, 2019-2025
40 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,575 · 2020: $614 · 2021: $1,284 · 2022: $7,088 · 2023: $2,190 · 2024: $2,647 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,607 · Consulting Fee: $1,000 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,607.42 |
| Consulting Fee | $1,000.00 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,000.00 | 2022 | |
| Abbvie INC. | $2,246.37 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,219.70 | 2019-2025 | |
| Journey Medical Corporation | $1,135.95 | 2020-2025 | |
| Janssen Biotech, INC. | $684.84 | 2019-2025 | Tremfya |
| Merz North America, INC. | $675.76 | 2019-2023 | Xeomin |
| Galderma Laboratories, L.P. | $652.02 | 2020-2025 | Aklief, Nemluvio, Oracea |
| E.R. Squibb & Sons, L.L.C. | $622.90 | 2022-2025 | Sotyktu |
| Pfizer INC. | $614.61 | 2019-2025 | |
| Genzyme Corporation | $539.96 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $497.91 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $486.26 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Regeneron Healthcare Solutions, INC. | $482.10 | 2019-2025 | Dupixent |
| Leo Pharma INC. | $443.04 | 2019-2025 | Adbry |
| Lilly USA, LLC | $430.92 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $323.64 | 2019-2022 | |
| Almirall LLC | $317.07 | 2019-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $312.76 | 2019-2023 | |
| Dermavant Sciences, INC. | $290.06 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $250.10 | 2023-2025 | Zoryve |
| Ucb, INC. | $230.72 | 2019-2025 | Bimzelx |
| Incyte Corporation | $158.09 | 2021-2024 | Opzelura |
| Amgen INC. | $117.17 | 2022-2025 | Otezla, Otezla |
| Dermira, INC. | $102.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.41 | 2023-2024 | Cyltezo, Spevigo |
| Sanofi-Aventis U.S. LLC | $59.16 | 2019 | |
| Botanix Sb INC | $54.58 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $50.74 | 2020-2021 | |
| Sebela Pharmaceuticals INC. | $47.71 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $45.68 | 2025 | Oxistat |
| Celgene Corporation | $39.86 | 2019 | |
| Blueprint Medicines Corporation | $22.64 | 2024 | Ayvakit |
| Genentech USA, INC. | $22.60 | 2021 | |
| Mylan Pharmaceuticals INC. | $21.94 | 2019 | |
| Biofrontera INC. | $21.85 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Lnhc, INC | $21.68 | 2025 | Zelsuvmi |
| Encore Dermatology INC. | $17.67 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $17.25 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.40 | 2024 | Ycanth |
| Strata Skin Sciences, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Witt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.